DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,053 filers reported holding DANAHER CORPORATION in Q2 2023. The put-call ratio across all filers is 0.79 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $868,728 | -7.9% | 3,477 | -7.9% | 0.02% | -7.7% |
Q1 2024 | $942,943 | +8.5% | 3,776 | +0.5% | 0.03% | 0.0% |
Q4 2023 | $869,144 | -59.4% | 3,757 | -56.5% | 0.03% | -61.8% |
Q3 2023 | $2,142,095 | -12.8% | 8,634 | -15.6% | 0.07% | -5.6% |
Q2 2023 | $2,455,680 | -85.4% | 10,232 | -84.7% | 0.07% | -86.2% |
Q1 2023 | $16,846,858 | -83.4% | 66,842 | -82.5% | 0.52% | -83.2% |
Q4 2022 | $101,469,004 | -4.3% | 382,296 | -6.9% | 3.11% | -6.0% |
Q3 2022 | $106,044,000 | -8.5% | 410,562 | -10.2% | 3.30% | +2.2% |
Q2 2022 | $115,933,000 | -26.3% | 457,294 | -14.8% | 3.23% | -14.5% |
Q1 2022 | $157,406,000 | -0.8% | 536,618 | +11.3% | 3.78% | +13.5% |
Q4 2021 | $158,609,000 | +13.8% | 482,080 | +5.3% | 3.33% | -3.1% |
Q3 2021 | $139,403,000 | +10.6% | 457,899 | -2.5% | 3.44% | +8.5% |
Q2 2021 | $126,026,000 | +27.9% | 469,617 | +7.3% | 3.17% | +17.0% |
Q1 2021 | $98,505,000 | +66.3% | 437,644 | +64.1% | 2.71% | +60.4% |
Q4 2020 | $59,239,000 | +2641.3% | 266,676 | +2557.5% | 1.69% | +2540.6% |
Q3 2020 | $2,161,000 | +539.3% | 10,035 | +425.1% | 0.06% | +481.8% |
Q2 2020 | $338,000 | +27.5% | 1,911 | 0.0% | 0.01% | +10.0% |
Q1 2020 | $265,000 | -10.2% | 1,911 | -0.4% | 0.01% | +11.1% |
Q4 2019 | $295,000 | +4.2% | 1,919 | -2.1% | 0.01% | 0.0% |
Q3 2019 | $283,000 | +1.1% | 1,960 | 0.0% | 0.01% | 0.0% |
Q2 2019 | $280,000 | -28.4% | 1,960 | -33.8% | 0.01% | -35.7% |
Q1 2019 | $391,000 | +15.7% | 2,960 | -9.6% | 0.01% | +16.7% |
Q4 2018 | $338,000 | +12.3% | 3,275 | +18.3% | 0.01% | +20.0% |
Q3 2018 | $301,000 | +14.0% | 2,768 | +3.6% | 0.01% | +11.1% |
Q2 2018 | $264,000 | +0.8% | 2,673 | 0.0% | 0.01% | -10.0% |
Q1 2018 | $262,000 | +5.6% | 2,673 | 0.0% | 0.01% | 0.0% |
Q4 2017 | $248,000 | +8.3% | 2,673 | 0.0% | 0.01% | +11.1% |
Q3 2017 | $229,000 | +0.4% | 2,673 | -0.9% | 0.01% | 0.0% |
Q2 2017 | $228,000 | -13.0% | 2,698 | -12.0% | 0.01% | -10.0% |
Q1 2017 | $262,000 | -99.4% | 3,067 | -99.4% | 0.01% | -99.4% |
Q4 2015 | $46,930,000 | +17.5% | 505,276 | +7.8% | 1.65% | +16.1% |
Q3 2015 | $39,954,000 | – | 468,889 | – | 1.42% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |